![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
EU WC
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
Erythromycin Lactobionate for Injection, USP is indicated in treatment of infections caused by susceptible strains of designated organisms when oral administration is not possible or when severity of infection requires immediate high serum levels of erythromycin.
Lead Product(s): Erythromycin Lactobionate
Therapeutic Area: Infections and Infectious Diseases Product Name: Erythromycin Lactobionate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
Erythromycin Lactobionate for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible.
Lead Product(s): Erythromycin Lactobionate
Therapeutic Area: Infections and Infectious Diseases Product Name: Erythromycin Lactobionate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2022